Plain-English translation of NCT05863234 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called to see if it can safely and effectively treat aggressive NK-cell leukemia, a rare type of blood cancer. Researchers will give the medication as an infusion into your vein and carefully monitor how your body responds to it. The study will help doctors understand the right dose and whether this treatment can help patients with this aggressive cancer.
Aggressive NK-cell leukemia is a rare and serious blood cancer that is difficult to treat with standard chemotherapy. This trial exists to explore whether this new medication might offer patients with this disease a new treatment option.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as a continuous intravenous infusion (a tube in your vein) at the hospital. The study will start with a low dose and gradually increase it as researchers learn how safe it is. You'll have regular check-ups and blood tests to monitor how the medication is working and how you're tolerating it. The trial expects to enroll about 7 patients total.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Japan
Safety & dosing / Early efficacy
Sponsor
Hiroshima University Hospital
Collaborators
Kyoto University Hospital, Hokkaido University Hospital
Enrollment target
~7 participants
Started
September 2023
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kiyoshi Ando
Hiroshima University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.